Oxaliplatin-based Chemotherapy Shows Promise in Elderly Patients with Metastatic Colorectal Cancer

Strategic Insights -

According to a recent study published in Frontiers in Oncology, researchers from Hebei Medical University have conducted a meta-analysis to evaluate the efficacy and safety of oxaliplatin-based chemotherapy as a first-line treatment in elderly patients with metastatic colorectal cancer (mCRC). The study found that oxaliplatin significantly improved tumor response rates compared to control regimens, and was associated with improved overall survival (OS) and progression-free survival (PFS) in patients aged 65 and older.

Key Takeaways:

  • The global burden of colorectal cancer continues to rise, with elderly populations disproportionately affected, and oxaliplatin's clinical utility in older adults remains debated.
  • The meta-analysis included 7 randomized controlled trials (RCTs) with 1,839 patients, comparing oxaliplatin-based chemotherapy to non-oxaliplatin regimens in patients aged 65 and older with mCRC.
  • Oxaliplatin significantly improved tumor response rates, with an overall response rate (ORR) of 34.6% compared to 12.2% in control regimens.
  • Oxaliplatin was associated with improved overall survival (OS) and progression-free survival (PFS) in patients aged 65 and older, with hazard ratios of 0.73 (95% CI 0.57-0.94) and 0.76 (95% CI 0.60-0.96), respectively.
  • The study also found that oxaliplatin was associated with increased grade 3-4 adverse events, including neutropenia, diarrhea, and fatigue.
  • Future trials must integrate biomarker-driven approaches to optimize therapeutic precision in aging populations.
  • Shaoqing Fan, Handong Wang, Zeming Zhao, and Haiqian Wang were co-authors of the study.

Statistics:

  • 34.6% - Overall response rate (ORR) of oxaliplatin-based chemotherapy
  • 12.2% - Overall response rate (ORR) of control regimens
  • 1,839 - Total number of patients in the 7 RCTs
  • 7 - Number of RCTs included in the meta-analysis
  • 65 - Minimum age criterion for patient inclusion
  • 0.73 - Hazard ratio for overall survival (OS) with oxaliplatin vs. control regimens
  • 0.76 - Hazard ratio for progression-free survival (PFS) with oxaliplatin vs. control regimens
  • 60% - Percentage of patients who experienced grade 3-4 adverse events

Sources:

  • Efficacy and Safety of Oxaliplatin-based Chemotherapy As First-line Treatment In Elderly Patients With Metastatic Colorectal Cancer: a Meta-analysis. Frontiers in Oncology, 2025;15.
  • Research Data from Hebei Medical University Update Understanding of Colon Cancer (Efficacy and Safety of Oxaliplatin-based Chemotherapy As First-line Treatment In Elderly Patients With Metastatic Colorectal Cancer: a Meta-analysis). Immunotherapy Weekly. May 21, 2025; p 1416.